ClinicalTrials.gg

Program

greziprubart

Also written as “STSA-1002 injection”, “STSA-1002 Injection” and “STSA-1002 subcutaneous injection”.

Its studies are mostly in Respiratory Distress Syndrome · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, led by Staidson (Beijing) Biopharmaceuticals.

Furthest: phase 3, since Sep 28, 20257 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Staidson (Beijing) Biopharmaceuticals71 open or runningphase 3since Sep 28, 2025Aug 19, 2021none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 19, 2021First study: phase 1 study in HealthyFirst studyNCT05032144 · 40 enrolled · United States
  2. Dec 8, 2021Phase 1 study in HealthyNCT05166837 · 52 enrolled · China
  3. Aug 1, 2022Phase 1 study in Healthy SubjectNCT05497635 · 26 enrolled · China
  4. Sep 26, 2022Phase 1 study in Healthy SubjectNCT05559125 · 50 enrolled · China
  5. Dec 23, 2022Phase 1 study in Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisNCT05702983 · 20 enrolled · United States
  6. Sep 8, 2023Phase 2 study in Respiratory Distress SyndromeNCT06038916 · 47 enrolled · China
  7. Sep 28, 2025Phase 3 study in Respiratory Distress SyndromeNCT07208591 · 406 planned · China

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07208591Respiratory Distress Syndrome · China3RecruitingJul 2026406
NCT06038916Respiratory Distress Syndrome · China2CompletedMar 20, 202547
NCT05702983Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis · United States1CompletedApr 11, 202320
NCT05559125Healthy Subject · China1TerminatedMar 26, 202450
NCT05497635Healthy Subject · China1CompletedApr 6, 202326
NCT05166837Healthy · China1CompletedJan 12, 202352
NCT05032144Healthy · United States1CompletedMar 31, 202240

How it is read

Names in the registry

  • “STSA-1002 injection”, 11 entries
  • “STSA-1002 Injection”, 3 entries
  • “STSA-1002 subcutaneous injection”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.